NCT06954428 - Clinical Trial of Intranasal Delivery of NT-301 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 20, 2025

Primary Completion Date

October 28, 2025

Study Completion Date

December 28, 2025

Conditions

Tolerability of NT-301 Nasal SprayPharmacokinetics of NT-301 Nasal SpraySafety of NT-301 Nasal SprayPerformance of NT-301 Nasal Spray Device

Interventions

COMBINATION_PRODUCT

NT-301 1 mg

unidose of 1 mg apomorphine through nasal spray

COMBINATION_PRODUCT

NT-301 2 mg

unidose of 2 mg apomorphine through nasal spray

COMBINATION_PRODUCT

Placebo 1 mg

Matching Placebo to NT-301 1 mg

COMBINATION_PRODUCT

Placebo 2 mg

Matching Placebo to NT-301 2 mg

COMBINATION_PRODUCT

Placebo 3 mg

Matching Placebo to NT-301 3 mg

COMBINATION_PRODUCT

NT-301 3 mg

unidose apomorphine nasal spray 3 mg

COMBINATION_PRODUCT

NT-301 4 mg

unidose apomorphine nasal spray 4 mg

COMBINATION_PRODUCT

Placebo 4 mg

Matching placebo to NT-301 4 mg

Trial Locations (2)

RECRUITING

CMAX Clinical Research Center Pty Limited, Adelaide

NOT_YET_RECRUITING

CMAX, Adelaide